Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
Anil GuptaYaneicy Gonzalez-RojasErick JuarezManuel Crespo CasalJaynier MoyaDiego R FalciElias SarkisJoel SolisHanzhe ZhengNicola ScottAndrea L CathcartChristy M HebnerJennifer SagerErik MogalianCraig TippleAmanda PeppercornElizabeth AlexanderPhillip S PangAlmena FreeCynthia BrinsonMelissa AldingerAdrienne E Shapironull nullPublished in: The New England journal of medicine (2021)
Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).